Transitional ePRO Diary Liver (Transitional-ePRO)
Condition(s) studied
Study summary
The study is part of the MACROLIVER Project, whose main objective is to create a digital tool for patients and caregivers for the management of liver disease that allows the optimization of therapy and/or the treatment process, even remotely. Such a tool not only reduces the movement of patients who are by definition fragile, but also enables the optimization of access and care by a multidisciplinary team. This tool is intended to support doctors and patients, but in no way replaces normal clinical practice. This study aims to explore the specificities of patients experiencing the transition from the pediatric ward to the adult ward in order to identify risk and protective factors that influence psychological well-being at both an individual and relational level. In order to gather all the information about the patients attending the transitional clinic and to obtain a more complete and truthful clinical-psychological picture, the study also includes the collection of retrospective data of the transplanted patients.
Eligibility
Primary outcome measure(s)
- four-item Morisky Medication Adherence Scale (MGLS) — 3 months
MGLS is used to assess non-adherence to therapy. The MGLS includes four questions with yes/no response options, resulting in a score from 0 to 4. Based on this score, there are 3 levels of adherence: high, medium and low adherence with 0, 1-2 and 3-4 points respectively. Scores below 2 indicate a lack of adherence to therapy, while scores greater than or equal to 3 indicate adherence to therapy.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| ASST-Papa Giovanni XXIII | Bergamo | MILANO | Recruiting |
More FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS trials in Italy
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06342557 on ClinicalTrials.gov ↗ ← All trials in Italy